Ray Therapeutics secures U.S. Food and Drug Administration RMAT designation for RTx-015, an optogenetic gene therapy showing early promise in restoring vision in retinitis pigmentosa.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Ray Therapeutics has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration for its lead candidate RTx-015, an investigational optogenetic gene therapy for patients with retinitis pigmentosa (RP).
RMAT designation is awarded to regenerative therapies targeting serious conditions where early clinical data indicate potential to address unmet medical needs. The designation provides benefits such as intensive FDA guidance, streamlined development pathways, and eligibility for priority review, helping accelerate the path toward potential approval.
Retinitis pigmentosa is a group of rare, inherited retinal disorders characterized by progressive degeneration of photoreceptor cells, leading to night blindness, loss of peripheral vision, and eventual severe vision impairment. Current treatment options are limited and largely focus on slowing disease progression rather than restoring vision.
RTx-015 is designed as a one-time intravitreal gene therapy that delivers a bioengineered, highly light-sensitive protein to retinal cells. This approach reprograms surviving retinal cells to respond to light, aiming to restore functional vision independent of the underlying genetic mutation. This mutation-agnostic strategy could make the therapy applicable across a broad RP patient population.
The therapy is currently being evaluated in clinical studies in patients with advanced RP. Early findings supporting the RMAT designation suggest a favorable safety profile along with initial signs of visual function improvement. As the program advances, the company is prioritizing endpoints that reflect real-world visual capabilities and meaningful gains in quality of life.
In parallel, Ray Therapeutics is developing RTx-021, a second optogenetic candidate targeting retinal bipolar cells for macular diseases, including Stargardt disease and geographic atrophy associated with age-related macular degeneration.
References
Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa, 01 April 2026, https://raytherapeutics.com/ray-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-rtx-015-in-retinitis-pigmentosa/
About the Writer
Samiksha Vikram Jadhav is a B.Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She has a keen interest in healthcare advancements, clinical research, medical writing, and emerging therapies. Her work focuses on presenting developments in the pharmaceutical and healthcare sectors through clear and accurate scientific communication.